New drug aims to halt lung decline in scarred lungs
Disease control
Ongoing
This phase 2 trial tests whether the investigational drug CAL101 can slow the loss of lung function in adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. About 150 participants will receive either CAL101 or a placebo by IV infusion once a month for 6…
Phase: PHASE2 • Sponsor: Calluna Pharma AS • Aim: Disease control
Last updated May 14, 2026 12:06 UTC